Montaine Lion , El Chérif Ibrahim , Elodie Caccomo-Garcia , Julie Bourret , Guillaume Cinquanta , Olfa Khalfallah , Nicolas Glaichenhaus , Laetitia Davidovic , Philippe Courtet , Gustavo Turecki , Eleni Tzavara , Raoul Belzeaux
{"title":"A specific GPR56/ADGRG1 splicing isoform is associated with antidepressant response in major depressive disorder","authors":"Montaine Lion , El Chérif Ibrahim , Elodie Caccomo-Garcia , Julie Bourret , Guillaume Cinquanta , Olfa Khalfallah , Nicolas Glaichenhaus , Laetitia Davidovic , Philippe Courtet , Gustavo Turecki , Eleni Tzavara , Raoul Belzeaux","doi":"10.1016/j.euroneuro.2025.01.001","DOIUrl":null,"url":null,"abstract":"<div><div>Major Depressive Episode (MDE) is one of the most common psychiatric disorders. Often difficult to treat, this disease is one of the leading causes of suicide. A recent study showed an association between <em>GPR56/ADGRG1</em> mRNA, MDE and response to antidepressant treatment in blood and in brain. Among <em>GPR56</em> splicing variant, the S4 isoform has recently been associated with microglial synaptic pruning, while microglia are already known as a central player in MDE. Therefore, we hypothesized that S4 is the specific isoform associated to MDE and antidepressant response. To test our hypothesis, an <em>in silico</em> analysis was first performed to identify the different proteins and transcript isoforms of <em>GPR56</em>. This analysis allowed to design PCR and qPCR primers. <em>GPR56</em> total, S4 and S3 were assessed by RT-qPCR in leukocytes from a cohort of 46 MDE patients including non-responders (NR, <em>n</em> = 31) and responders-remitters (R, <em>n</em> = 17) to antidepressant treatment. We replicated the result of one of our previous studies, which described an increase in total <em>GPR56</em> mRNA in Rs. Additionally, we observed that this variation differs among mRNA splicing variants, with S4 exhibiting a similar pattern of variation while S3 shows no significant change. The differences observed withstood statistical correction for covariates of interest such as smoking, gender and suicidal ideation, demonstrating the robustness of the model. These findings confirm our hypothesis that certain mRNA splicing variants of <em>GPR56</em> may play a more significant role in depression. This study highlighted a link between the <em>GPR56-S4</em> and response to antidepressant treatment.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 5-14"},"PeriodicalIF":6.1000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X2500001X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Major Depressive Episode (MDE) is one of the most common psychiatric disorders. Often difficult to treat, this disease is one of the leading causes of suicide. A recent study showed an association between GPR56/ADGRG1 mRNA, MDE and response to antidepressant treatment in blood and in brain. Among GPR56 splicing variant, the S4 isoform has recently been associated with microglial synaptic pruning, while microglia are already known as a central player in MDE. Therefore, we hypothesized that S4 is the specific isoform associated to MDE and antidepressant response. To test our hypothesis, an in silico analysis was first performed to identify the different proteins and transcript isoforms of GPR56. This analysis allowed to design PCR and qPCR primers. GPR56 total, S4 and S3 were assessed by RT-qPCR in leukocytes from a cohort of 46 MDE patients including non-responders (NR, n = 31) and responders-remitters (R, n = 17) to antidepressant treatment. We replicated the result of one of our previous studies, which described an increase in total GPR56 mRNA in Rs. Additionally, we observed that this variation differs among mRNA splicing variants, with S4 exhibiting a similar pattern of variation while S3 shows no significant change. The differences observed withstood statistical correction for covariates of interest such as smoking, gender and suicidal ideation, demonstrating the robustness of the model. These findings confirm our hypothesis that certain mRNA splicing variants of GPR56 may play a more significant role in depression. This study highlighted a link between the GPR56-S4 and response to antidepressant treatment.
期刊介绍:
European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.